Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harmony Biosciences HoldingsHRMY +1.35%94 Net Current Asset Value is $7.58 as of Jun. 2026, which is 39% below its 10-year median of 12.36. GuruFocus rates HRMY with a GF Score™ of 94/100 and a GF Value™ of $46.81 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 935 Biotechnology companies, Harmony Biosciences Holdings ranks worse than 54.76% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Harmony Biosciences Holdings's net current asset value per share for the quarter that ended in Jun. 2026 was $7.58.
The historical rank and industry rank for Harmony Biosciences Holdings's Net Current Asset Value or its related term are showing as below:
HRMY'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.41 Med: 12.36 Max: 1277.67
Current: 5.11
During the past 8 years, the highest Price-to-Net-Current-Asset-Value Ratio of Harmony Biosciences Holdings was 1277.67. The lowest was 3.41. And the median was 12.36.
HRMY's Price-to-Net-Current-Asset-Value is ranked worse than 54.76% of 935
companies
in the Biotechnology industry
Industry Median: 4.72
vs HRMY: 5.11
Harmony Biosciences Holdings (NAS:HRMY) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Harmony Biosciences Holdings Net Current Asset Value Related Terms
Harmony Biosciences Holdings Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harmony Biosciences Holdings Net Current Asset Value Chart
HRMY vs SION, URGN, PVLA: Net Current Asset Value Comparison
For the Biotechnology subindustry, Harmony Biosciences Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harmony Biosciences Holdings Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Harmony Biosciences Holdings's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $7.58 mean?
Harmony Biosciences Holdings (HRMY) has a Net Current Asset Value of $7.58 as of Jun. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Harmony Biosciences Holdings and its competitors. This is 39% below median its historical median of 12.36. Over the past decade, Harmony Biosciences Holdings' Net Current Asset Value has ranged from 3.41 to 1,277.67. According to the industry distribution chart, Harmony Biosciences Holdings ranks #512 out of 935 companies in the Biotechnology industry, placing it in the top 54.8%.
Is Harmony Biosciences Holdings' Net Current Asset Value too high?
Harmony Biosciences Holdings' current Net Current Asset Value of $7.58 is 39% below median its 10-year median of 12.36. Over the past 10 years, this metric has ranged from a low of 3.41 to a high of 1,277.67. The Biotechnology industry median Net Current Asset Value is 4.72. Harmony Biosciences Holdings' value of $7.58 is 60.6% above this industry median. Based on the distribution chart, Harmony Biosciences Holdings ranks #512 out of 935 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Harmony Biosciences Holdings has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' Net Current Asset Value compare to SION and URGN?
According to the Biotechnology industry distribution chart, Harmony Biosciences Holdings ranks #512 out of 935 companies for Net Current Asset Value. This places Harmony Biosciences Holdings in the lower half of its industry. The industry median Net Current Asset Value is 4.72. Harmony Biosciences Holdings' value of $7.58 is 60.6% above this benchmark. Historically, Harmony Biosciences Holdings' own Net Current Asset Value has ranged from 3.41 to 1,277.67 over the past decade. While the company's 10-year median is 12.36 vs. the industry median of 4.72, Harmony Biosciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.72, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harmony Biosciences Holdings's current Net Current Asset Value of $7.58 is 60.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Harmony Biosciences Holdings and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harmony Biosciences Holdings's current Net Current Asset Value is $7.58, which is 39% below median its own 10-year median of 12.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.81, compared to a current price of $38.74 — trading 17.2% below its estimated fair value. The current Net Current Asset Value is $7.58, which is 39% below median its 10-year median of 12.36 and 60.6% above the Biotechnology industry median of 4.72. Harmony Biosciences Holdings' overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current Net Current Asset Value is $7.58 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?
Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued.
The current stock price of $38.74 is trading 17.2% below its estimated GF Value™ of $46.81.
GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.
Key valuation signals for HRMY:
Net Current Asset Value: $7.58 (39% below median its 10-year median of 12.36)
GF Value™: $46.81 vs. price of $38.74 (17.2% below fair value)
Industry Position: 60.6% above the Biotechnology median (#512 of 935)
No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
94GF Score
Get the complete analysis for HRMY
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRMY has been successfully added to your 
